


## Corrections

**CELL BIOLOGY.** For the article “Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR $\gamma$  agonist,” by Thomas M. McIntyre, Aaron V. Pontsler, Adriana R. Silva, Andy St. Hilaire, Yong Xu, Jerald C. Hinshaw, Guy A. Zimmerman, Kotaro Hama, Junken Aoki, Hiroyuki

Arai, and Glenn D. Prestwich, which appeared in number 1, January 7, 2003, of *Proc. Natl. Acad. Sci. USA* (**100**, 131–136; First Published December 26, 2002; 10.1073/pnas.0135855100), Fig. 4 should have appeared in color. The correct figure and its legend appear below.



**Fig. 4.** LPA stimulates lipid accumulation, CD36 expression, and oxidized LDL uptake through a PPAR-responsive element. (a) LPA stimulates monocyte uptake of oxidized LDL. Freshly elutriated human monocytes were allowed to interact with an anti-ICAM3-coated well, which leads to rapid PPAR $\gamma$  expression (13), and then stimulated, or not (negative, oxLDL), with oleoyl LPA. Some cells were then briefly exposed to oxidized LDL before intracellular lipid stores were visualized with oil red O stain. (b) LPA increases the expression of CD36 on the surface of primary human monocytes. Monocytes engaging anti-ICAM3 were treated or not with LPA, and then recovered by gentle scraping and washing by centrifugation before their surface CD36 was assessed by flow cytometry. (c) LPA and the LPA analogs XY4 and XY8 stimulate CD36 promoter function only when the PPRE is present. RAW264.7 cells were transfected with the human CD36 promoter containing the PPRE (CD36<sup>-273</sup>) or a reporter that lacks only this element (CD36<sup>-261</sup>) and then stimulated with oleoyl LPA, azPC, XY4, or XY8. Expression of luciferase normalized to  $\beta$ -galactosidase was determined as above. (d) Anti-CD36 blocks LPA-stimulated accumulation of cholesterol from oxidized LDL. Freshly isolated human monocytes were treated as in a, but after being preincubated with a blocking anti-CD36 antibody before exposure to oxidized LDL.

www.pnas.org/cgi/doi/10.1073/pnas.0538065100

**MEDICAL SCIENCES.** For the article “A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor,” by Achim A. Jungbluth, Elisabeth Stockert, H. J. Su Huang, Vincent P. Collins, Keren Coplan, Kristin Iversen, Denise Kolb, Terrance J. Johns, Andrew M. Scott, William J. Gullick, Gerd Ritter, Leonard Cohen, Matthew J. Scanlan, Webster K. Cavenee, and Lloyd J. Old, which appeared in number 2, January 21, 2003, of *Proc. Natl. Acad. Sci. USA* (**100**, 639–644; First Published January 6, 2003; 10.1073/pnas.232686499), the author name Webster K. Cavenee should have appeared as Webster K. Cavenee. The corrected author line appears below. The online version has been corrected.

**Achim A. Jungbluth, Elisabeth Stockert, H. J. Su Huang, Vincent P. Collins, Keren Coplan, Kristin Iversen, Denise Kolb, Terrance J. Johns, Andrew M. Scott, William J. Gullick, Gerd Ritter, Leonard Cohen, Matthew J. Scanlan, Webster K. Cavenee, and Lloyd J. Old**

www.pnas.org/cgi/doi/10.1073/pnas.0530200100

**PHARMACOLOGY.** For the article “*In vivo* activation of a mutant  $\mu$ -opioid receptor by antagonist: Future direction for opiate pain treatment paradigm that lacks undesirable side effects,” by Ping-Yee Law, Jesse W. Yang, Xiaohong Guo, and Horace H. Loh, which appears in number 4, February 18, 2003, of *Proc. Natl. Acad. Sci. USA* (**100**, 2117–2121; First Published January 13, 2003; 10.1073/pnas.0334906100), the author line contained the following errors. Dr. Yang should be the first author. In addition, Dr. Yang’s name should have appeared as Wanling Yang, not Jesse W. Yang. The corrected author line is shown below.

**Wanling Yang, Ping-Yee Law, Xiaohong Guo, and Horace H. Loh**

www.pnas.org/cgi/doi/10.1073/pnas.0630447100